FDA Fast Tracks Antibody Therapy for Pulmonary Infections Including Cystic Fibrosis

Clarametyx Biosciences announced it had received fast track and qualified infectious disease product (QIDP) designations from the FDA for the company’s investigational antibody therapy CMTX-101. The therapy is being studied to treat people with cystic fibrosis (CF) who are affected by chronic bacterial pulmonary infections, including nontuberculous mycobacterial (NTM) lung disease, non-CF bronchiectasis (NCFB), and chronic obstructive pulmonary disease (COPD).¹

“The receipt of both fast track and QIDP designations from the FDA underscores CMTX-101's potential as an innovative therapy for patients suffering from chronic respiratory conditions. We look forward to working even closer with FDA to expedite the approval of a new therapy for patients suffering from difficult-to-treat pulmonary conditions,” Clarametyx CEO David V. Richards said in a news release.¹

With this news and the company securing funding with its Series A financing from existing investors to support ongoing pipeline activities, Clarametyx is expanding its phase 2 study and aims to have full enrollment by the end of the year.²

Study Parameters and Interim Results

The company announced a positive interim analysis in June. The ongoing randomized, double-blind, placebo-controlled clinical trial is assessing CMTX-101 as an adjunctive therapy to standard of care antibiotics in people with CF, evaluating safety and tolerability, pharmacokinetics, immunogenicity, reduction of pulmonary Pseudomonas aeruginosa burden, and additional exploratory end points.

An interim analysis of data from the first 21 participants enrolled met the prespecified criteria to continue the trial at both 5 and 30 mg/kg dose levels. Participants treated with CMTX-101 demonstrated a reduction in P aeruginosa based on prespecified statistical criteria and CMTX-101 was shown to be present in the sputum of all treated participants. Importantly, CMTX-101 was generally well tolerated, consistent with the findings reported in a prior clinical study, and no antidrug antibodies were detected.

Learn more: Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis Patients

About the Agent

CMTX-101 is an investigational immune-enabling antibody therapy in development to address chronic respiratory disease exacerbation and lung function decline. The therapy is designed to precisely and rapidly destroy the universal underlying, proinflammatory structure of bacterial biofilms to undermine extracellular bacterial defenses and enable more effective antibiotic and immune intervention. Because the target is universally present across bacteria, the approach can treat a range of bacterial infections and pathogen types.

The goal of treatment is to dramatically improve the effectiveness of innate immune system effectors and antibiotic therapies, thereby addressing inflammation pathways driven by the biofilm state.

References
1. Clarametyx Biosciences announces FDA grant of fast track and qualified infectious disease product designations for CMTX-101. News release. Clarametyx. August 4, 2025. Accessed August 5, 2025. https://www.businesswire.com/news/home/20250804750253/en/Clarametyx-Biosciences-Announces-FDA-Grant-of-Fast-Track-and-Qualified-Infectious-Disease-Product-Designations-for-CMTX-101
2. Clarametyx Biosciences announces positive interim analysis in phase 2a study evaluating CMTX-101 for infections associated with cystic fibrosis. News release. Clarametyx. June 16, 2025. Accessed August 5, 2025.
https://clarametyx.com/positive-interim-analysis-in-phase-2a-study/